Details for Patent: 9,364,489
✉ Email this page to a colleague
Title: | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Abstract: | The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. |
Inventor(s): | Anzalone; Luigi (West Chester, PA), Villani; Frank J. (Perkasie, PA), Teleha; Christopher A. (Fort Washington, PA), Feibush; Penina (Ambler, PA), Fegely; Barry (Quakertown, PA) |
Assignee: | Forest Tosara Limited (Dublin, IE) |
Filing Date: | Jul 22, 2015 |
Application Number: | 14/806,465 |
Claims: | 1. A method of treating a mammal suffering from irritable bowel syndrome comprising administering to said mammal an effective amount of a Form .alpha. crystal of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. 2. The method of claim 1, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 14.0, 14.3, and 14.7 degrees 2-theta. 3. The method of claim 1, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 10.2, 11.3, 14.0, 14.3, and 14.7 degrees 2-theta. 4. The method of claim 1, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 10.2, 11.3, 11.8, 14.0, 14.3, 14.7, 16.1, and 18.3 degrees 2-theta. 5. The method of claim 1, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially as shown in Table 1. 6. The method of claim 1, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially similar to the powder X ray diffraction peaks of FIG. 1. 7. The method of claim 1, wherein said Form .alpha. crystal is characterized by a thermal gravimetric analysis (TGA) substantially similar to the TGA in FIG. 2. 8. The method of claim 1, wherein said Form .alpha. crystal is characterized by a differential scanning calorimetry (DSC) measurement substantially similar to the DSC in FIG. 3. 9. A method of treating a mammal suffering from pain comprising administering to said mammal an effective amount of a Form .alpha. crystal of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. 10. The method of claim 9, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 14.0, 14.3, and 14.7 degrees 2-theta. 11. The method of claim 9, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 10.2, 11.3, 14.0, 14.3, and 14.7 degrees 2-theta. 12. The method of claim 9, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 10.2, 11.3, 11.8, 14.0, 14.3, 14.7, 16.1, and 18.3 degrees 2-theta. 13. The method of claim 9, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially as shown in Table 1. 14. The method of claim 9, wherein said Form .alpha. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially similar to the powder X ray diffraction peaks of FIG. 1. 15. The method of claim 9, wherein said Form .alpha. crystal is characterized by a thermal gravimetric analysis (TGA) substantially similar to the TGA in FIG. 2. 16. The method of claim 9, wherein said Form .alpha. crystal is characterized by a differential scanning calorimetry (DSC) measurement substantially similar to the DSC in FIG. 3. 17. A method of treating a mammal suffering from irritable bowel syndrome comprising administering to said mammal an effective amount of a Form .beta. crystal of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. 18. A method of treating a mammal suffering from pain comprising administering to said mammal an effective amount of a Form .beta. crystal of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phen- yl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. 19. The method of claim 17, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, and 15.2 degrees 2-theta. 20. The method of claim 17, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, 14.9, 15.2, and 22.1 degrees 2-theta. 21. The method of claim 17, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, 14.9, 15.2, 22.1, 25.6, 27.4, and 30.4 degrees 2-theta. 22. The method of claim 17, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially as shown in Table 2. 23. The method of claim 17, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially similar to the powder X ray diffraction peaks of FIG. 1. 24. The method of claim 17, wherein said Form .beta. crystal is characterized by a thermal gravimetric analysis (TGA) substantially similar to the TGA in FIG. 4. 25. The method of claim 17, wherein said Form .beta. crystal is characterized by a differential scanning calorimetry (DSC) measurement substantially similar to the DSC in FIG. 5. 26. The method of claim 18, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, and 15.2 degrees 2-theta. 27. The method of claim 18, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, 14.9, 15.2, and 22.1 degrees 2-theta. 28. The method of claim 18, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks at about 11.0, 12.4, 14.9, 15.2, 22.1, 25.6, 27.4, and 30.4 degrees 2-theta. 29. The method of claim 18, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially as shown in Table 2. 30. The method of claim 18, wherein said Form .beta. crystal is characterized by a powder X-ray diffraction pattern having powder X-ray diffraction peaks substantially similar to the powder X ray diffraction peaks of FIG. 1. 31. The method of claim 18, wherein said Form .beta. crystal is characterized by a thermal gravimetric analysis (TGA) substantially similar to the TGA in FIG. 4. 32. The method of claim 18, wherein said Form .beta. crystal is characterized by a differential scanning calorimetry (DSC) measurement substantially similar to the DSC in FIG. 5. |